The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review

Movement Disorders

Volumn 15, Issue 1, 2000, Pages 56-64

  Ramaker, Claudia ^a   Van De Beek, Willem Johan T ^a   Finken, Martijn J J ^a   Van Hilten, Bob J J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bromocriptine; Motor complications; Parkinson's disease; Systematic review

Indexed keywords

BROMOCRIPTINE; LEVODOPA; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VOMITING;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0033971117     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200001)15:1<56::AID-MDS1010>3.0.CO;2-2     Document Type: Article

References (22)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-964.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-155.
3. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths Scientific, 1982:96-122.
4. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
5. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49:283-293.
6. Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989;Jun(suppl):29-37.
7. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet 1974;2: 1355-1356.
8. Stern G, Lees A. Bromocriptine in Parkinson's disease. Br J Hosp Med 1978;20:666-670.
9. Hardie RJ, Lees AJ, Stern GM. The controversial role of bromocriptine in Parkinson's disease. Clin Neuropharmacol 1985;8:150-155.
10. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985;37:217-227.
11. Calne DB. Dopaminergic agonists in the treatment of Parkinson's disease. In: Klawans HL, ed. Clinical Neuropharmacology. New York, NY: Raven Press, 1978:153-166.
12. Mackenzie RA, Lance JW. A double-blind trial of bromocriptine in Parkinson's disease. Med J Aust 1978;2(suppl):27-28.
13. Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Acta Neurol Scand 1985;72:157-170.
14. Temlett JA, Ming A, Saling M, et al. Adjunctive therapy with bromocriptine in Parkinson's disease. S Afr Med J 1990;78:680-685.
15. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
16. Schneider E, Fischer PA. Bromocritin inder Behandlung der fortgeschrittenen Stadien des Parkinson-Syndroms. Dtsch Med Wochenschr 1982;107:175-179.
17. Bateman DN, Coxon A, Legg NJ, Reid JL. Treatment of the on-off syndrome in parkinsonism with low dose bromocriptine in combination with levodopa. J Neurol Neurosurg Psychiatry 1978;41: 1109-1113.
18. Gron U. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease. Acta Neurol Scand 1977;56:269-273.
19. Jansen EN. Bromocriptine in levodopa response-losing parkinsonism. A double blind study. Eur Neurol 1978;17:92-99.
20. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
21. Hill AB. Anonymous Principles of Medical Statistics, 7th ed. London: The Lancet Limited, 1961:259.
22. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-639.